Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT05631249
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sotorasib 120Mg Tab — DRUG
    Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up

Study Details

This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.

Key Dates

Start date
Dec 13, 2022
Status verified
May 2025
Primary completion
Dec 12, 2027
Completion
Dec 12, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sotorasib treatment
    Sotorasib : 120 mg, once a day, per os, until progression, unacceptable toxicity, death or lost to follow-up

Primary Outcome Measure

Tumor response assessment [ Time Frame: at 4 months after treatment start ]

Central Contacts

Related Studies